[HTML][HTML] Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
Y Liu, J Wang, X Hu, Z Pan, T Xu, J Xu, L Jiang… - Drug Resistance …, 2023 - Elsevier
Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …
Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer
L Zhang, Z Li, M Zhang, H Zou, Y Bai, Y Liu, J Lv, L Lv… - Medical Oncology, 2023 - Springer
Most patients with differentiated thyroid cancer have a good prognosis after radioactive
iodine-131 treatment, but there are still a small number of patients who are not sensitive to …
iodine-131 treatment, but there are still a small number of patients who are not sensitive to …
1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism
S Wang, JT Shi, XR Wang, HX Mu, XT Wang, KY Xu… - Bioorganic …, 2023 - Elsevier
Abstract The PI3K/AKT/mTOR signaling pathway is one of the most common abnormal
activation pathways in tumor cells, and has associated with multiple functions such as tumor …
activation pathways in tumor cells, and has associated with multiple functions such as tumor …
[HTML][HTML] BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category
The use of radioiodine therapy (RIT) is debated in intermediate-risk differentiated thyroid
cancer (DTC) patients. The understanding of the molecular mechanisms involved in the …
cancer (DTC) patients. The understanding of the molecular mechanisms involved in the …
[HTML][HTML] Multi-omics and management of follicular carcinoma of the thyroid
TE Luvhengo, I Bombil, A Mokhtari, MS Moeng… - Biomedicines, 2023 - mdpi.com
Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland,
accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The …
accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The …
[HTML][HTML] Single institution experience in the management of locally advanced (pT4) differentiated thyroid carcinomas
L Sessa, C De Crea, N Voloudakis, F Pennestri'… - Annals of Surgical …, 2024 - Springer
Background Locally infiltrating (T4) differentiated thyroid carcinomas (DTC) represent a
challenge. Surgical strategy and adjuvant therapy should be planned balancing morbidity …
challenge. Surgical strategy and adjuvant therapy should be planned balancing morbidity …
[HTML][HTML] Clinical efficacy of iodine-125 (125I) seed implantation in patients with iodine-refractory differentiated thyroid cancer
Y Su, J Wang, L Huang, L Xie, X Yu… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Patients with radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) are
resistant to radioactive iodine-131 (131 I) treatment, and the clinical treatment for these …
resistant to radioactive iodine-131 (131 I) treatment, and the clinical treatment for these …
Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis
SK Parvathareddy, AK Siraj, N Siraj… - Frontiers in …, 2024 - frontiersin.org
Background Radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) has
received increasing attention due to its poor prognosis. However, outcomes may vary …
received increasing attention due to its poor prognosis. However, outcomes may vary …
[HTML][HTML] Lysicamine Reduces Protein Kinase B (AKT) Activation and Promotes Necrosis in Anaplastic Thyroid Cancer
MT Rodrigues, APP Michelli, GF Caso, PR de Oliveira… - Pharmaceuticals, 2023 - mdpi.com
Anaplastic thyroid cancer (ATC) is an aggressive form of thyroid cancer (TC), accounting for
50% of total TC-related deaths. Although therapeutic approaches against TC have improved …
50% of total TC-related deaths. Although therapeutic approaches against TC have improved …
Molecular Perspectives in Radioactive Iodine Theranostics: Current Redifferentiation Protocols for Mis-Differentiated Thyroid Cancer
SA Gulec, C Benites, ME Cabanillas - Journal of Clinical Medicine, 2024 - mdpi.com
Thyroid cancer molecular oncogenesis involves functional dedifferentiation. The initiating
genomic alterations primarily affect the MAPK pathway signal transduction and generate an …
genomic alterations primarily affect the MAPK pathway signal transduction and generate an …